Glycobiology Advance Access first published online on March 1, 2007
This version published online on March 6, 2007
Glycobiology, doi:10.1093/glycob/cwm017
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Selective clearance of glycoforms of a complex glycoprotein pharmaceutical caused by terminal N-acetylglucosamine is similar in humans and cynomolgus monkeys
2 Departments of Analytical Chemistry
3 Pharmacokinetics and Metabolism, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA
4 Department of Clinical Pharmacology, F. Hoffmann - La Roche Ltd., CH-4070, Basel, Switzerland
1 To whom correspondence should be addressed: Tel 650-225-6264, FAX 650-225-3554, email: jeb{at}gene.com
Received on November 17, 2006; revised on February 10, 2007; accepted on February 11, 2007
To understand how the carbohydrate moieties of a recombinant glycoprotein affected its pharmacokinetic properties, the glycan distribution was directly assessed from serial blood samples taken during pharmacokinetic studies in cynomolgus monkeys and humans. The protein studied was an immunoadhesin (lenercept), containing an Fc domain from human immunoglobulin (IgG-1) and two copies of the extensively glycosylated extra cellular domain of tumor necrosis factor receptor p55. The protein was recovered in pure form using a dual column, immunoaffinity-reversed-phase-high pressure liquid chromatographic (RP-HPLC) method. The glycans were released and analyzed by Matrix Assisted Laser Desorption Ionization Time of Flight (MALDI-TOF) mass spectrometry. Alternatively, trypsin was used to obtain glycopeptides, and these were analyzed by MALDI-TOF. The composition vs. time profiles show that the distribution of glycans in the Fc domain was not altered over 10 days of circulation, consistent with their sequestration in the interior of the protein. However, the glycan composition in the receptor domain was changed dramatically in the first 24 hrs and then remained relatively constant. Analysis of the acidic glycans (derived exclusively from the receptor domain) showed that, in the rapid initial phase of clearance, glycans carrying terminal N-acetylglucosamine (tGlcNAc) were selectively cleared from circulation. This phenomenon occurred similarly in humans and cynomolgus monkeys. Sialic acid content and terminal galactose showed only small changes. These data confirm the correlation of tGlcNAc and half life of the molecule, and support the hypothesis that the mannose receptor (which can also bind tGlcNAc) causes the variable clearance of this molecule.
Key words: immunoadhesin / lenercept / terminal N-acetylglucosamine / selective glycan clearance / IgG1 Fc glycans / terminal galactose
5 Current address: Myriad Pharmacueticals, Inc., Salt Lake City, UT 84108
6 Current address: Amgen Inc., Thousand Oaks, CA
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. Hossler, S. F Khattak, and Z. J. Li Optimal and consistent protein glycosylation in mammalian cell culture Glycobiology, September 1, 2009; 19(9): 936 - 949. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Chen, Y D. Liu, and G. C Flynn The effect of Fc glycan forms on human IgG2 antibody clearance in humans Glycobiology, March 1, 2009; 19(3): 240 - 249. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G.-C. Gil, W. H Velander, and K. E Van Cott Analysis of the N-glycans of recombinant human Factor IX purified from transgenic pig milk Glycobiology, July 1, 2008; 18(7): 526 - 539. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Powlesland, T. Fisch, M. E. Taylor, D. F. Smith, B. Tissot, A. Dell, S. Pohlmann, and K. Drickamer A Novel Mechanism for LSECtin Binding to Ebola Virus Surface Glycoprotein through Truncated Glycans J. Biol. Chem., January 4, 2008; 283(1): 593 - 602. [Abstract] [Full Text] [PDF]
|
|